Substance P signaling mediates BMP‐dependent heterotopic ossification

Heterotopic ossification (HO) is a disabling condition associated with neurologic injury, inflammation, and overactive bone morphogenetic protein (BMP) signaling. The inductive factors involved in lesion formation are unknown. We found that the expression of the neuro‐inflammatory factor Substance P (SP) is dramatically increased in early lesional tissue in patients who have either fibrodysplasia ossificans progressiva (FOP) or acquired HO, and in three independent mouse models of HO. In Nse‐BMP4, a mouse model of HO, robust HO forms in response to tissue injury; however, null mutations of the preprotachykinin (PPT) gene encoding SP prevent HO. Importantly, ablation of SP+ sensory neurons, treatment with an antagonist of SP receptor NK1r, deletion of NK1r gene, or genetic down‐regulation of NK1r‐expressing mast cells also profoundly inhibit injury‐induced HO. These observations establish a potent neuro‐inflammatory induction and amplification circuit for BMP‐dependent HO lesion formation, and identify novel molecular targets for prevention of HO. J. Cell. Biochem. 112: 2759–2772, 2011. © 2011 Wiley‐Liss, Inc.

[1]  A. Stark,et al.  Occurrence of substance P in bone repair under different load comparison of straight and angulated fracture in rat tibia , 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[2]  J. Kessler,et al.  Animal Models of Typical Heterotopic Ossification , 2010, Journal of biomedicine & biotechnology.

[3]  R. Vink,et al.  Kinin Receptor Antagonists as Potential Neuroprotective Agents in Central Nervous System Injury , 2010, Molecules.

[4]  J. Parvizi,et al.  Mast cells and hypoxia drive tissue metaplasia and heterotopic ossification in idiopathic arthrofibrosis after total knee arthroplasty , 2010, Fibrogenesis & tissue repair.

[5]  C. López-Otín,et al.  Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation , 2009, Proceedings of the National Academy of Sciences.

[6]  C. Jacobs,et al.  Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro. , 2009, Bone.

[7]  J. Kessler,et al.  Differential effects of BMP signaling on parvalbumin and somatostatin interneuron differentiation , 2009, Development.

[8]  R. Vink,et al.  Substance P is Associated with the Development of Brain Edema and Functional Deficits after Traumatic Brain Injury , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  H. Hong,et al.  A new role of substance P as an injury-inducible messenger for mobilization of CD29+ stromal-like cells , 2009, Nature Medicine.

[10]  J. Eisman,et al.  Critical Interplay Between Neuropeptide Y and Sex Steroid Pathways in Bone and Adipose Tissue Homeostasis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  R. Awatramani,et al.  Dysregulation of Local Stem/Progenitor Cells as a Common Cellular Mechanism for Heterotopic Ossification , 2009, Stem cells.

[12]  Tomokazu Fukuda,et al.  BMP type I receptor inhibition reduces heterotopic ossification , 2008, Nature Medicine.

[13]  R. Pignolo,et al.  Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP) , 2008, Journal of Bone and Mineral Metabolism.

[14]  U. Lerner,et al.  Osteotropic effects by the neuropeptides calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. , 2008, Journal of musculoskeletal & neuronal interactions.

[15]  R. Pignolo,et al.  Hematopoietic stem-cell contribution to ectopic skeletogenesis. , 2007, The Journal of bone and joint surgery. American volume.

[16]  A. Kreicbergs,et al.  Opioid peptides and receptors in joint tissues: Study in the rat , 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[17]  C. Sheen,et al.  Neuropeptides activate human mast cell degranulation and chemokine production. , 2006, Immunology.

[18]  E. Sternberg,et al.  Brain-immune interactions and disease susceptibility , 2005, Molecular Psychiatry.

[19]  K. Tracey,et al.  Autonomic neural regulation of immunity , 2005, Journal of internal medicine.

[20]  R. Teshima,et al.  N-cadherin plays a role in the synapse-like structures between mast cells and neurites. , 2004, Biological & pharmaceutical bulletin.

[21]  W. Gomes,et al.  Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. , 2004, The American journal of pathology.

[22]  K. Bost,et al.  Non-neuronal mammalian tachykinin expression. , 2004, Frontiers in bioscience : a journal and virtual library.

[23]  S. Stock,et al.  MicroCT quantification of in vitro bone resorption of neonatal murine calvaria exposed to IL-1 or PTH. , 2004, Journal of structural biology.

[24]  P. Devillier,et al.  mRNA expression of tachykinins and tachykinin receptors in different human tissues. , 2004, European journal of pharmacology.

[25]  Kevin J. Tracey,et al.  The inflammatory reflex , 2002, Nature.

[26]  Carl Nathan,et al.  Points of control in inflammation , 2002, Nature.

[27]  Ricardo Saban,et al.  Mast cells mediate substance P-induced bladder inflammation through an NK(1) receptor-independent mechanism. , 2002, American journal of physiology. Renal physiology.

[28]  Teruo Tanaka,et al.  Tachykinins and tachykinin receptors in bone , 2002, Microscopy research and technique.

[29]  L. Thompson,et al.  Mast cell involvement in fibrodysplasia ossificans progressiva. , 2001, Human pathology.

[30]  Teruo Tanaka,et al.  Substance P and substance P receptors in bone and gingival tissues , 2001, Medical Electron Microscopy.

[31]  A. Janecka,et al.  Substance P: transmitter of nociception (Minireview). , 2000, Endocrine regulations.

[32]  T. Okada,et al.  Functional neurokinin NK-1 receptor expression in rat peritoneal mast cells , 1999, Inflammation Research.

[33]  T. Sugimoto,et al.  Neonatal primary neuronal death induced by capsaicin and axotomy involves an apoptotic mechanism , 1998, Brain Research.

[34]  T. Tanaka,et al.  Light- and electron-microscopic study of the distribution of axons containing substance P and the localization of neurokinin-1 receptor in bone , 1998, Cell and Tissue Research.

[35]  J. Polak,et al.  Fracture Healing and Callus Innervation After Peripheral Nerve Resection in Rats , 1998, Clinical orthopaedics and related research.

[36]  C. Pothoulakis,et al.  Neurokinin-1 (NK-1) receptor is required in Clostridium difficile- induced enteritis. , 1998, The Journal of clinical investigation.

[37]  C. Epstein,et al.  Primary afferent tachykinins are required to experience moderate to intense pain , 1998, Nature.

[38]  C. Maggi,et al.  The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles , 1998, Neuropeptides.

[39]  C. Hildebrand,et al.  The developmental skeletal growth in the rat foot is reduced after denervation , 1997, Anatomy and Embryology.

[40]  C. Pothoulakis,et al.  Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Burke,et al.  A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  U. Höpken,et al.  Neurogenic Amplification of Immune Complex Inflammation , 1996, Science.

[43]  K. Messner,et al.  Transient local presence of nerve fibers at onset of secondary ossification in the rat knee joint , 1995, Anatomy and Embryology.

[44]  U. Holzer‐Petsche,et al.  Central versus peripheral site of action of the tachykinin NK1‐antagonist RP 67580 in inhibiting chemonociception , 1995, British journal of pharmacology.

[45]  T. Kaneko,et al.  Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat , 1994, The Journal of comparative neurology.

[46]  S. Savastano,et al.  Hypothalamic-pituitary-adrenal axis and immune system. , 1994, Acta neurologica.

[47]  A. Naukkarinen,et al.  MAST CELL TRYPTASE AND CHYMASE ARE POTENTIAL REGULATORS OF NEUROGENIC INFLAMMATION IN PSORIATIC SKIN , 1994, International journal of dermatology.

[48]  C. Nast,et al.  Protective function of extrinsic sensory neurons in acute rabbit experimental colitis. , 1994, Gastroenterology.

[49]  A. Zelenetz,et al.  W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. , 1993, Development.

[50]  Y. Yonekawa,et al.  Alterations of a 200 kDa Neurofilament in the Rat Hippocampus after Forebrain Ischemia , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[51]  P. Laduron,et al.  A non‐peptide NK1‐receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically , 1993, British journal of pharmacology.

[52]  A. Barr,et al.  Non‐peptide antagonists, CP‐96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors , 1993, British journal of pharmacology.

[53]  R. Hargreaves,et al.  The non‐peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats , 1993, British journal of pharmacology.

[54]  R. Jaenisch,et al.  Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system , 1992, Cell.

[55]  P. Mantyh.  Substance P and the Inflammatory and Immune Response , 1991, Annals of the New York Academy of Sciences.

[56]  J. Puzas,et al.  Heterotopic ossification: Clinical and cellular aspects , 1991, Calcified Tissue International.

[57]  P. K. Dey,et al.  Alteration of substance P after trauma to the spinal cord: An experimental study in the rat , 1990, Neuroscience.

[58]  M. Nerenberg,et al.  Transgenic mice expressing β-galactosidase in mature neurons under neuron-specific enolase promoter control , 1990, Neuron.

[59]  S. Galli,et al.  Substance P-induced augmentation of cutaneous vascular permeability and granulocyte infiltration in mice is mast cell dependent. , 1989, The Journal of clinical investigation.

[60]  A. Harmar,et al.  Synthesis, and central and peripheral axonal transport of substance P in a dorsal root ganglion-nerve preparation in vitro , 1982, Brain Research.

[61]  S. Hunt,et al.  Biochemical and anatomical observations on the degeneration of peptide-containing primary afferent neurons after neonatal capsaicin , 1981, Neuroscience.

[62]  S Ochs,et al.  Routing of transported materials in the dorsal root and nerve fiber branches of the dorsal root ganglion. , 1978, Journal of neurobiology.

[63]  W. O. McClure,et al.  INHIBITION OF AXOPLASMIC TRANSPORT BY COLCHICINE, PODOPHYLLOTOXIN, AND VINBLASTINE: AN EFFECT ON MICROTUBULES * , 1975, Annals of the New York Academy of Sciences.

[64]  A. Davis,et al.  Heterotopic ossification has some nerve. , 2010, Critical reviews in eukaryotic gene expression.

[65]  J. Forsberg,et al.  Heterotopic ossification in wartime wounds. , 2010, Journal of surgical orthopaedic advances.

[66]  R. Kalluri,et al.  Conversion of vascular endothelial cells into multipotent stem-like cells , 2010, Nature Medicine.

[67]  N. Cullen,et al.  Heterotopic ossification: pharmacologic options. , 2009, The Journal of head trauma rehabilitation.

[68]  R. Vink,et al.  Substance P in traumatic brain injury. , 2007, Progress in brain research.

[69]  B. Davis,et al.  Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity , 2007, Nature Protocols.

[70]  In Ho Choi,et al.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva , 2006, Nature Genetics.

[71]  Sudha Srivastava,et al.  Substance P: structure, function, and therapeutics. , 2004, Current topics in medicinal chemistry.

[72]  J. Quinn,et al.  Tachykinin expression in cartilage and function in human articular chondrocyte mechanotransduction. , 2003, Arthritis and rheumatism.

[73]  T. Nagasawa,et al.  Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouse. , 1996, Brain research. Molecular brain research.

[74]  K. Lafferty.  The immunologic network. , 1988, Transplantation proceedings.

[75]  D. Payan,et al.  Substance P and immunoregulation. , 1987, Federation proceedings.

[76]  McGillis Jp,et al.  Substance P and immunoregulation. , 1987 .

[77]  P. Wall,et al.  Substance P in spinal cord dorsal horn decreases following peripheral nerve injury. , 1981, Brain research.